FDA 483 - Henan Lihua Pharmaceutical Co., Ltd. - December 11, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Henan Lihua Pharmaceutical Co., Ltd., an API manufacturer in Anyang, China, revealed significant issues with record control and data integrity. Inspectors found uncontrolled blank manufacturing records and QA stamps, indicating a lack of proper documentation management. Additionally, the firm failed to maintain complete QC records due to software configurations that allowed data overwriting and the use of duplicate file names for analytical runs.
ID · d7788260-5fe7-4a72-a949-a255bf586131